Le Lézard
Classified in: Health
Subject: ACC

Number of shares and votes in Medivir AB on 31 January 2024


STOCKHOLM, Jan. 31, 2024 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024. Both issues have been previously announced through separate press releases. The new issues resulted in an increase of 48,664,647 ordinary shares respectively 7,547,170 ordinary shares, which entails an increase of 56,211,817 ordinary shares in total.

Today, the last trading day of the month, there are in total 112,917,968 shares in Medivir, of which 112,053,218 ordinary shares and 864,750 class C-shares, which together carrying 112,139,693 votes. One ordinary share entitles to one (1) vote and one class C-share entitles to one tenth (1/10) of a vote.

For additional information, please contact;

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected] 

This information is such information that Medivir AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was sent for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor set out above at the publication of this press release.

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com

The following files are available for download:

https://mb.cision.com/Main/652/3919657/2572985.pdf

Press release (PDF)

SOURCE Medivir


These press releases may also interest you

at 15:20
ArkeaBiotm, a leading ag-biotech start-up developing a vaccine to reduce livestock methane emissions, today announced the close of a $26.5 million Series A financing round. The raise was led by current investor Breakthrough Energy Ventures (BEV), and...

at 14:55
According to Arizton's latest focus insight report, the US laboratory developed tests market is growing at a CAGR of 3.40% from 2023 to 2029....

at 14:45
The International Society for Pharmaceutical Engineering (ISPE) has announced featured speakers and a focus on digital innovation for the 2024 ISPE Biotechnology Conference. The focus on integrating new technologies and pioneering strategies aligns...

at 14:29
iHealth Labs, Inc. (iHealth®), a leading provider of digital health solutions, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the company's 3-in-1 COVID-19/Flu A&B Rapid Test Kit...

at 14:15
The CDC now estimates nearly half a million people will contract Lyme disease in the United States each year. However, most people do not realize how Lyme disease can cause diverse, devastating symptoms in some patients. The range of symptoms is...

at 14:15
Frederick, MD-based Genesis + HOCL introduces two HOCl atomizing machines for Air Quality Awareness Week. Genesis is the sole U.S. distributor of this technology, previously only available in Japan and South Korea, bringing the Genesis 2.6 and UX4 to...



News published on and distributed by: